Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
INSYS Therapeutics Inc clinical trials
The registry lists 45 studies whose lead sponsor is INSYS Therapeutics Inc. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Feb 1, 2019.
Registry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to INSYS Therapeutics Inc.
- INSYS Therapeutics Inc45 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 45 of 45.
- A Study to Compare Bioavailability of Naloxone Nasal Spray and Naloxone Hydrochloride (HCl) Intramuscular Injection (IM) in Healthy VolunteersCompletedNCT03827629Phase 1
- A Study to Compare Bioavailability of Naloxone Nasal Spray, Naloxone Hydrochloride (HCl) Intravenous (IV) and Intramuscular Injection (IM) in Healthy VolunteersCompletedNCT03827642Phase 1
- Study of Buprenorphine Sublingual Spray Versus Standard of Care Narcotic Therapy for the Treatment of Post-Operative PainCompletedNCT03254459Phase 2
- Cannabidiol Oral Solution for Treatment of Refractory Infantile SpasmsTerminatedNCT02551731Phase 2
- Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure DisorderCompletedNCT02318602Phase 3
- Efficacy and Safety Study of LE-DT to Treat Metastatic Castrate Resistant Prostate CancerWithdrawnNCT01188408Phase 2
- Fentanyl Sublingual Spray for the Treatment of Moderate to Severe Post-Operative PainCompletedNCT02915978Phase 2
- Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Dravet SyndromeWithdrawnNCT02318563Phase 3
- Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Lennox-Gastaut SyndromeWithdrawnNCT02318537Phase 3
- Fentanyl Sublingual Spray for the Treatment of Acute Procedure-related Pain in a Monitored SettingWithdrawnNCT02138409Phase 3
- Study of Buprenorphine Sublingual Spray for the Treatment of Moderate to Severe PainCompletedNCT02634788Phase 3
- Buprenorphine Sublingual Spray for the Treatment of Moderate to Severe PainTerminatedNCT02310581Phase 3
- Study to Explore Effectiveness of Sublingual Fentanyl Spray in Emergency Department Patients With Acute PainWithdrawnNCT02137525Phase 2
- Cannabidiol Oral Solution in Pediatric Participants With Treatment-resistant Seizure DisordersCompletedNCT02324673Phase 1/2
- Fentanyl Sublingual Spray in Opioid Naive ParticipantsCompletedNCT02641340Phase 1
- Comparative Bioavailability of Dronabinol Oral Solution in Healthy VolunteersCompletedNCT02604992Not applicable
- Fentanyl Sublingual Spray and Fentanyl Citrate Intravenous (IV) in Opioid Naive SubjectsCompletedNCT02576353Phase 1
- Study of Buprenorphine-Naloxone Sublingual Spray and Suboxone® Sublingual Film in Healthy VolunteersCompletedNCT02477267Phase 1
- Possible New Therapy for Advanced CancerTerminatedNCT01832974Phase 1
- Exploratory Bioavailability of Fentanyl Sublingual Spray Under Fasting ConditionsCompletedNCT02138396Not applicable
- Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: Continuous Infusion for 10 DaysWithdrawnNCT00024674Phase 1
- Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant GliomaCompletedNCT00024570Phase 1/2
- Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: IV Infusion QOD x Six DosesWithdrawnNCT00024687Phase 1
- Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With Recurrent Malignant GliomaWithdrawnNCT00378235Phase 1/2
- A Study of the Abuse Potential of Dronabinol in Recreational Cannabinoid UsersCompletedNCT02094599Phase 1
- Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainCompletedNCT00538850Phase 3
- Long-term Safety and Efficacy Study of Fentanyl Sublingual Spray for the Treatment of Breakthrough Cancer PainCompletedNCT00538863Phase 3
- Fentanyl Sublingual Spray in Treating Opioid-tolerant Cancer Patients With or Without Oral MucositisCompletedNCT00956254Phase 3
- Pharmacokinetic Study of Fentanyl 400 µg Sublingual Spray, Actiq® 400 µg Transmucosally, and Fentanyl Citrate Injection 100 µg Intravenously (iv)CompletedNCT01780233Phase 1
- Efficacy and Safety Study of LE-DT to Treat Locally Advanced or Metastatic Pancreatic CancerCompletedNCT01186731Phase 2
- Efficacy and Safety Study of LEP-ETU to Treat Metastatic Breast CancerCompletedNCT01190982Phase 2
- Comparative Bioavailability of Dronabinol Oral Solution Versus Branded Capsule 5 mg Under Fasting ConditionsCompletedNCT01448772Phase 1
- IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant GliomaCompletedNCT00089427Phase 1
- Liposome Encapsulated SN38 (LE-SN38) in Patients With Advanced CancerCompletedNCT00046540Phase 1
- Study to Determine the Maximum Tolerated Dose of LErafAON in Patients With Advanced CancerCompletedNCT00100672Phase 1
- Comparison of Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) and Taxol® Pharmacokinetics in Patients With Advanced CancerCompletedNCT00100139Phase 1
- Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) in Patients With Advanced CancerCompletedNCT00080418Phase 1
- Liposome Encapsulated Docetaxel (LE-DT) in Patients With Solid TumorsCompletedNCT01151384Phase 1
- Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma PatientsCompletedNCT00024557Phase 1
- Study of Liposome Encapsulated Mitoxantrone (LEM) in Patients With Advanced CancerCompletedNCT00024492Phase 1
- The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma MultiformeCompletedNCT00076986Phase 3
- Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant GliomaCompletedNCT00064779Phase 1
- Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant GliomaCompletedNCT00041587Phase 1/2
- Study to Determine Maximum Tolerated Dose of LErafAON Combined With Radiotherapy in Patients With Advanced MalignanciesCompletedNCT00024648Phase 1
- Study to Determine the Maximum Tolerated Dose of LErafAON in Patients With Advanced Solid TumorsCompletedNCT00024661Phase 1